Jon Campbell serves the health economics and outcomes research field as senior vice president for health economics at the Institute for Clinical and Economic Review (ICER). He is a leader in value assessment methods and application. As a member of ICER’s Senior Management Team, Jon oversees the growth of ICER’s health economics efforts and leads the continued innovation of ICER’s value assessment methodology. He is a bridge builder and solution seeker. Jon builds bridges within the global health economics community through active engagement with ICER’s Health Economic Council and through active leadership and participation in health technology assessment societies and agencies. Further, he seeks creative value assessment solutions for its diverse stakeholders, while keeping my eye on patients and improving their health.
Jon has participated in over 25 ISPOR conferences. He has served ISPOR for many years on the conference scientific review committee and through coauthoring working group and task force reports, being an ISPOR chapter faculty mentor, and teaching ISPOR short courses. He is an author of over 250 manuscripts and abstracts in the field of value assessment, over 20 ICER assessments, and holds an affiliate faculty position within the Center for Evaluation of Value and Risk in Health at Tufts University School of Medicine. Jon is a former associate professor at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences.
One of Jon’s passions is making good decisions and helping others do the same. He applies this passion by using evidence-based approaches to improve pharmaceutical and other medical technology population-level decision making. These efforts facilitate the sustainability of pharmaceutical and other medical technologies, leading to value-based healthcare for all Americans. Jon is also passionate about mentoring others. He enjoys supporting others and their contributions that benefit the health economics and outcomes research field. Jon’s training includes graduate degrees in pharmaceutical outcomes research (PhD) and biostatistics (MS) from the University of Washington. He graduated Phi Beta Kappa with Bachelor of Arts degrees in mathematics and chemistry from St Olaf College.
ISPOR Vision Statement by Jon Campbell
With over 15 years of ISPOR service, I am vested in supporting ISPOR in making meaningful changes in health. I am well aligned and motivated to achieve ISPOR goals in research and education. Thank you for considering my candidacy for ISPOR director.
ISPOR is a leading international hub for diverse stakeholders within the health economics and outcomes research ecosystem. Our ecosystem includes patients and patient engagement organizations, payer and policy makers, researchers and academics, the life sciences industry and consultants, assessors and regulators, and healthcare providers. When core value sets are shared across stakeholders, positive change is not only possible, but probable. ISPOR and I are well aligned in our core values that include maintaining high scientific and ethical standards; being stakeholder-driven with clear, measurable, and impactful goals; ensuring good governance; and seeking diversity and social responsibility. A motivating factor for me in joining ICER’s leadership team was to experience and engage with diverse stakeholders within value assessment. Within my leadership role at ICER, I am thankful for the opportunity to listen to diverse voices within our value assessment ecosystem and for the opportunity to continue making improvements in methods in alignment with these diverse voices.
As an ISPOR director, I will enhance and act out aspects of ISPOR's strategic initiatives. Specifically, my interests and expertise are well aligned to act within the Scientific and Research Excellence and the Education and Training pillars. I am experienced and aligned with ISPOR's strategic initiatives in value assessment and engaging stakeholders. My unique contributions include my health technology assessor perspective alongside prior experience in academics and research. Novel value assessment ideas require a laboratory for testing and tailoring. I am well positioned to serve as a conduit for connecting researchers and assessors. Further, education and training remain critical to me. As our world continues to evolve, ISPOR education and training opportunities multiply. As ISPOR director, I will advocate for opportunities for ISPOR’s growing membership to access and experience the wealth of short courses and other training materials to build the next generation of practitioners and leaders. Finally, within areas of research and education, ISPOR is poised to break down traditional pillars. I am particularly interested in how our field can learn better from each other and where intersections in specialty niches can merge to strengthen their respective parts. For example, we are seeing observational real-world evidence merge with health technology assessment in innovative ways with room to grow. Opportunities abound for artificial intelligence and its applications in a learning and dynamic approach to value assessment. ISPOR is the ideal home to build such collaborative intersections as we are collectively rooted in scientific rigor and excellence, and we endeavor to provide quality evidence for improved decision making in health.